NAtive Collagen Type II In Healthy VoluntEers With Joint Discomfort

Inclusion Criteria:

• Males and non-pregnant females 30-65 years old with a Body Mass Index (BMI) ofapproximately 18 to 30 kg/m2. (see Section 4.0)

• Unilateral or bilateral knee discomfort for greater than 3 months.

• VAS score during knee movement between 30-50 mm after 7-day withdrawal of excludedmedications.

• Reach joint discomfort of 5/10 on a 11-point Likert scale ( score 0 to 10) within 10minutes of going up and down stairs.

• Clinical laboratory results that are within normal range or considered notclinically significant by the Principal Investigator.

• Be willing to participate in all scheduled visits, tests, and other trial proceduresaccording to the clinical protocol. To do so and be able of using the fitnesstracker, a phone or tablet compatible with the Fitbit app is required. (Apple iOS 12.2 or higher, Android OS 7.0 or higher.)

• Be willing to refrain from taking ibuprofen, aspirin or other Non-steroidalanti-inflammatory drugs (NSAIDs), or any other pain reliever (OTC (Over the Counter)or prescription) during the entire study other than acetaminophen (paracetamol) asrescue medication.

• Provide a signed and dated informed consent indicating that the subject has beeninformed of all pertinent aspects and possible risks associated with participationin the study.

• Be willing to refrain from taking dietary supplements during the entire study thathave any underlying joint benefit (collagen, glucosamine, chondroitin, MSM,Hyaluronic Acid, Turmeric, Natural Eggshell Membrane, Omega-3 fatty acids, PEA,Boswellia,...)

Exclusion Criteria:

• History of hypersensitivity to the rescue medication or any of the products used inthe study.

• Requirement of drugs to control joint discomfort.

• Regular drug intake to control any kind of pain.

• History of hypersensitivity to eggs, chicken, or fowl.

• History of Knee OA (OsteoArthritis), inflammatory arthropathy, RA (RheumatoidArthritis), OA (VAS score greater than 50), or Systemic Lupus Erythematosus.

• Hyperuricemia (>440 μmol/L), history of gout, or both.

• Exercising (intentionally) for more than 10 hours a week

• High intensity exercise for more than 5 hours a week

• Anticipation of surgery within the next 6 months.

• Recent injury in the target knee (past 4 months).

• History of congestive heart failure.

• Anticipated problems with product consumption.

• Evidence or history of clinically significant haematological, renal, endocrine,pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, ormalignancies within the last 5 years.

• High alcohol intake (>2 standard drinks per day) or use of recreational drugs (e.g.,cocaine, methamphetamine, marijuana, etc.).

• Females who are pregnant or lactating or planning to become pregnant.

• History of any mental illness that might impair the ability of subjects to provide awritten informed consent.

• Use of oral corticosteroid, indomethacin, SYSADOAs (symptomatic slow action drugosteoarthritis) within 3 months of Visit 1; topical treatment with corticosteroidswithin 1 week of visit 1, and consumption of Omega 3 fatty acids or any other jointhealth dietary supplements within 2 weeks preceding the treatment period.

• Consumed, ibuprofen, aspirin or other NSAIDS, or any other pain reliever (OTC orprescription), or any natural health product, (excluding vitamins) within 7 days offirst visit.

• Consumed acetaminophen (paracetamol) within 48 hours of randomization visit.

• Participation in any clinical trials within 30 days prior to first visit.

• Individuals following an energy restricted diet for weight loss